Aims: To determine the association between cardiovascular diseases (CVD) and SGLT2 inhibitors compared to sulfonylureas and dipeptidyl peptidase-4 (DPP4) inhibitors and to examine within-class effects of SGLT2 inhibitors.
| INTRODUCTION
Type 2 diabetes now affects more than 350 million patients worldwide, 1 putting these individuals at higher risk of developing micro-and macrovascular complications including cardiovascular diseases (CVDs). 2 Maintaining optimal glycaemic control can delay or reduce the risk of potential complications. 2 However, debate continues regarding which antihyperglycaemic drugs optimally reduce complications. Recent evidence from randomized clinical trials (RCTs)
suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as dapagliflozin, canagliflozin and empagliflozin, may exhibit cardioprotective effects. 3 For example, the Empagliflozin Cardiovascular
Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) reported a 14% reduction in the risk of CVD (nonfatal myocardial infarction [MI] and non-fatal stroke) and CVD-related death in the empagliflozin group compared to the placebo group. 4 Similarly, the Canagliflozin Cardiovascular Assessment Study (CANVAS) trial reported a lower risk of CVD events with canagliflozin compared to placebo (hazard ratio [HR] , 0.86; 95% confidence interval
[CI], 0.75, 0.97). 5 Subsequently, these results were supported by a meta-analysis of RCTs which found a net protective effect of SGLT2 inhibitors against major CVDs (relative risk [RR] , 0.85; 95% CI, 0.77, 0.93), heart failure (RR, 0.67; 95% CI, 0.55, 0.80) and all-cause death (RR, 0.79; 95% CI, 0.70, 0.88). 6 Although RCTs are the gold standard in assessing the effectiveness of medications, the restricted environment of RCTs limits generalizability to real-world settings and often does not allow for assessment of heterogeneity in treatment effects. Evidence generated using real-world data can complement RCTs in guiding prescribing decisions in clinical practice. 7, 8 Several observational studies have recently evaluated the cardiovascular safety of SGLT2 inhibitors among patients with type 2 diabetes. [9] [10] [11] [12] [13] [14] [15] [16] [17] One population-based study, which used data from the Health Improvement Network database, found that, compared to use of other glucose-lowering agents, the use of empagliflozin was associated with lower risk of all-cause mortality, irrespective of baseline CVD. 9 Similarly, the first analysis from the Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL) study and two follow-up analyses of the same study showed a lower risk of death and hospitalization as the result of heart failure with use of SGLT2 inhibitors compared to other glucoselowering medications (eg, sulfonylureas, thiazolidinediones [TZDs]) but showed no difference in incidence of non-fatal MI and non-fatal stroke. 10, 11, 13 In contrast, the most recent analyses of the CVD-REAL study and two other observational studies, which primarily focused on canagliflozin, reported a lower risk of non-fatal MI and non-fatal stroke but a higher risk of lower extremity amputation with the use of SGLT2 inhibitors compared to other glucose-lowering medications. 12, 14, 15, 17 In the first analysis of the CVD-REAL study, which included data from the United States and Europe, the reduction in risk of heart failure and death was reported across countries, regardless of variability in the use of SGLT-2 inhibitors, with canagliflozin dominating the United States and dapagliflozin dominating Europe, suggesting a class effect. 10 Similarly, the results of the CVD-REAL 2 study, which included Asian and Middle Eastern populations, suggested that reduction in cardiovascular outcomes (eg, MI, stroke) with the use of SGLT2 inhibitors was a class effect. 16 Although prior studies have suggested a class effect, none have explicitly evaluated the within-class effect of SGLT2 inhibitors.
Additionally, there has been conflicting evidence regarding the risk of amputation with the use of SGLT2 inhibitors. 18, 19 Therefore, our primary objectives were to (1) determine the incidence of CVD with the use of SGLT2 inhibitors compared to other oral, second-line glucose-lowering drugs, namely sulfonylureas and DPP-4 inhibitors, among patients with type 2 diabetes and (2) to compare the withinclass effects of SGLT2 inhibitors. Secondarily, we aimed to assess the association between use of SGLT2 inhibitors vs sulfonylureas or DPP-4 inhibitors on and the risk of hospitalization because of heart failure or of lower extremity amputation.
2 | METHODS
| Data source
We conducted a retrospective cohort study using the Truven Health The date of the dispensing of the first eligible prescription was designated as the index date. A new-user design, which avoids the biases introduced by including prevalent users, such as the underascertainment of early events or immortal time bias, was employed. 21, 22 Patients were considered to be exposed as long as they continued to refill their prescription, allowing a gap of 7 days or less between refills.
Patients were excluded if they had a diagnosis of type I diabetes (ICD- 
| Statistical analysis
Descriptive statistics were summarized using means for continuous variables and proportion for categorical variables. Demographics and clinical characteristics were compared between exposure groups using a chi-square test for categorical variables and independent t-test for continuous variables. Standardized differences were used to examine the balance in baseline characteristics post matching, where imbalance was defined as an absolute value higher than 0.2. 24, 25 Following propensity score matching, proportional hazard models were used to obtain the HR and associated 95% CI. Several sensitivity analyses were conducted to examine the robustness of study results, including the exclusion of TZDs and insulin users, and changing the outcome definition to primary diagnosis only. We further evaluated heterogeneity in treatment effect in selected subgroups of diabetic patients, including patients with baseline CVD vs those with baseline CVD, and those aged less than 65 years vs those 65 years and older. Separate propensity score matching was performed within each of the subgroup analyses and for each pair of within-class effect comparisons (eg, dapagliflozin vs DPP-4 inhibitors). For secondary analyses of lower extremity amputation, patients with a history of lower extremity amputation were excluded. All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, North Carolina).
| RESULTS
We Table 1 ). In both propensity-matched cohorts, patient characteristics including age, sex and presence of comorbid conditions were comparable. Table S1 summarizes baseline characteristics among the three groups before propensity score matching. Table 2 (Table 2) . We also observed a reduced risk of hospitalization because of heart failure with the use of SGLT2 inhibitors as compared to use sulfonylureas (HR, 0.48; 95% CI, 0.40, 0.57) and DPP-4 inhibitors (HR, 0.54; 95% CI, 0.48, 0.60).
| Incident cardiovascular disease

| Risk of lower extremity amputation
The crude incidence rates of lower extremity amputation were 1.5 per 1000 person-years in the SGLT2 inhibitor group and 1.9 in the sulfonylurea group. In the SGLT2 inhibitor vs DPP-4 inhibitor analysis, the crude incidence rates were 1.8 per 1000 person-years in the SGLT-2 inhibitor group and 1.9 per 1000 person-years in the DPP-4 inhibitor groups ( 
| Subgroup and sensitivity analyses
Results of subgroup and sensitivity analyses are shown in Tables 3   and 4 . In subgroup analyses, we found a lower risk of CVD among patients 65 years of age or younger who were exposed to SGLT2
inhibitors compared exposure to sulfonylureas (HR, 0.59; 95% CI, 
| DISCUSSION
In this large, contemporary cohort of patients with type 2 diabetes, we found that the use of SGLT2 inhibitors was associated with a 43%
to 50% reduced risk of developing nonfatal CVD when compared to use of sulfonylureas or to use of DPP-4 inhibitors. These results were consistent among patients with and without pre-existing CVD. We also found that use of SGLT2 inhibitors was associated with a 46% to 52% reduction in the risk of hospitalization because of heart failure, a finding that complements those reported in the EMPA-REG, CANVAS trials and in recent observational studies. [4] [5] [6] 10, 15, 17, 26 Finally, we observed a modestly lower risk of lower extremity amputation comparing use of SGLT2 inhibitors to use of sulfonylureas, but not to use of DPP-4 inhibitors.
Unlike the EMPA-REG OUTCOME trial and the CANVAS study, which compared SGLT2 inhibitors to placebo, the current study used active comparators which is more relevant to guidance concerning prescribing decisions in routine clinical practice. 4, 5 Observational studies, such as the CVD-REAL study, have compared SGLT2 inhibitors to other glucose-lowering agents, with conflicting findings. 10, 13, 16, 17 In the first follow-up analysis of the CVD-REAL study, the authors did not find a significant difference between use of dapagliflozin and use of DPP-4 inhibitors in risk of MI and stroke, but subsequent analyses reported a reduction in risk. 13 Compared to our study, the first followup analysis was limited by the small sample size (10 227 vs 66 633) and the outcome sources (outcome definition based on inpatient and outpatient claims vs inpatients claims only). Our case definition of MI was based only on inpatient discharge diagnoses as this approach has a high sensitivity (94%) and specificity (99%). 27 Additionally, the CVD-REAL study used a different exposure definition. Patients who received a comparator drug but switched to SGLT2 inhibitors were classified as SGLT2 inhibitor-exposed, whereas patients who received a comparator drug and died were classified as comparator-exposed.
To address this in our study, we employed an incident new-user design and we censored follow-up when patients switched from one drug to another. Two other recent analyses of real-world data reported findings similar to those of our study. 12, 15 In this study, we found no evidence of within-class effect in risk of CVD between the SGLT2 inhibitors dapagliflozin and canagliflozin.
Unfortunately, we were unable to examine empagliflozin because of the limited sample size in this group. Nevertheless, a class effect would appear to be supported by the fact that these drugs seem to exhibit similar effects on the metabolic and non-metabolic surrogate markers associated with cardiovascular risk. Qualitatively similar findings concerning cardiovascular risk have also been observed in the EMPA-REG OUTCOME and CANVAS studies. inhibitors comparably lowers uric acid and offer renoprotective effects, but these appear to be modest. CI, 0.76, 1.07). 11 Our findings, however, are consistent with those of the CVD-REAL 2 study which found that the beneficial effect of use of SGLT2 inhibitors extends to both low-and high-risk patients. 17 Additionally, although there was a minimal overlap in confidence intervals of the different age groups (>65 years, ≤65 years), the P value for interaction was not significant, suggesting an absence of difference in the cardiovascular benefits of use of SGLT2 inhibitors between the different age groups. 
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) and compared to use of DPP-4 inhibitors (Adimadhyam et al. 19 ). The results, however, are discordant with those from the EASEL study which found a higher risk of lower extremity amputation comparing SGLT-2 inhibitors to other glucose-lowering medications (HR, 1.99; 95% CI, 1.12, 3.51). 15 The discordant findings between the EASEL study and our own may be explained by a greater The clinical implications of the current analysis are several-fold.
First, our results suggest that SGLT2 inhibitors may be the preferred second-line oral agent, after metformin, for reducing cardiovascular risk in patients with type 2 diabetes. Although we were unable to directly assess the effect of underlying cardiovascular risk on the differential effects of treatment, our finding of no interaction between baseline CVD and reduced outcomes with use of SGLT2 inhibitors suggests that the preference for SGLT2 inhibitors may be prudent across the cardiovascular risk spectrum. However, the CVD benefits observed here also must be considered alongside other concerns, including greater costs with use of SGLT2 inhibitors.
The current study has several strengths. We used the Truven Marketscan database, which is nationally representative of patients enrolled in employer-based insurance programmes (approximately 55% of the US population) or with Medicare supplementary insurance.
This large sample size allowed us to examine the within-class effect of use of SGLT2 inhibitors between dapagliflozin and canagliflozin, and we adjusted for measured confounders using propensity score matching to minimize the impact of confounding by indication. Finally, we conducted numerous sensitivity analyses to ensure the robustness of our results.
Several limitations of this analysis should be noted. 
